Immuno-oncology therapy developer Forty Seven (NASDAQ:FTSV) jumps 62% premarket on average volume in reaction to Gilead Sciences’ (NASDAQ:GILD) $95.50 per share cash offer representing a total transaction value of ~$4.9B.
The deal should close next quarter.
https://seekingalpha.com/news/3547352-gilead-takes-out-forty-seven-for-4_9b
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.